Sökresultat

When in Sweden for their annual meeting, members of the European Huntington Association paid a visit to Lund on 28 August 2025. There they met with Åsa Petersén and Camilla Svensson, registered nurse, also working at the HD Clinic at Skåne University Hospital (SUS) in Lund, together with Åsa. Åsa showed them around the lab, demonstrated samples and talked about her research. The EHA team also got

https://www.huntington-research.lu.se/article/visit-european-huntington-association - 2026-09-13

On 9-11 September 2025 the Arturo Falaschi Conference “2nd biennial conference on TDP-43 function and dysfunction in disease” will be held in Trieste, Italy. Sofia Bergh will present her poster with the findings published earlier this summer in the article “TDP-43 overexpression in the hypothalamus drives neuropathology, dysregulates metabolism and impairs behavior in mice”.Link to the conference

https://www.huntington-research.lu.se/article/sofia-bergh-will-present-poster-tdp-43-conference - 2026-09-13

Åsa Petersén will give several talks at the conference, including one on emotions and behavior in HD, and she will also chair a session on clinical trials.The conference is arranged by the patients' organization, the European Huntington Association, and is open to all.Find out more about the conference on EHA:s webpage (opens in a new window).

https://www.huntington-research.lu.se/article/petersen-eha-conference-2025-bucharest - 2026-09-13

The National Board of Health and Welfare in Sweden has published updated information on Huntington disease on its’ webpage. These recent revisions of the text have been made by Professor Åsa Petersén, Lund University.Link to the National Board of Health and Welfare’s webpage – in Swedish only (opens in a new window).

https://www.huntington-research.lu.se/article/updated-information-hd-national-board-health-and-welfares-webpage - 2026-09-13

Professor Petersén comments on the recent positive topline results from a clinical trial with gene therapy in Huntington disease presented in a press release from uniQure. Last week, positive topline results from a clinical trial with gene therapy in Huntington disease were presented in a press release from uniQure. The news hit the headlines and spread fast through the HD community. Read Professo

https://www.huntington-research.lu.se/article/perspective-recent-positive-topline-results-gene-therapy-trial - 2026-09-13

The Swedish channel TV4 published the news on the HD clinical trials that were positively described in media in late September. Professor Åsa Petersén was interviewed about the findings by TV4 and she emphasizes the need for cautiousness when interpreting the results, as they are not yet published in a scientific magazine or reviewed by researchers not involved in the study. Link to the article on

https://www.huntington-research.lu.se/article/tv4-news-piece-hd-gene-therapy-trial - 2026-09-13

Petersén is invited to give a talk at the 2025 Family Gathering for the Scottish Huntington's Association with around 170 attendees on November 8, 2025 in Glasgow.Link to the programme at the association’s webpage (opens in a new window)

https://www.huntington-research.lu.se/article/petersen-gives-talk-scottish-huntingtons-association-meeting - 2026-09-13

The Swedish patients' organisation, RHS, held their yearly meeting in October 2025 and Professor Åsa Petersén was invited speaker. Petersén's talk addressed early symptoms in HD connected to research. The meeting was recorded and the films are now available on RHS' website.Link to the content at RHS' website - in Swedish only (opens in a new window)

https://www.huntington-research.lu.se/article/petersens-talk-rhs-meeting-2025 - 2026-09-13

Jennifer Oraha, PhD student in Åsa Peterséns's research group, has her first publication out. The article is based on her study of the effects of overexpression of TDP-43 or mHTT in AgRP-expressing neurons on metabolic, behavioral and neuropathological features in mice.FTD/ALS and HD share early traits when it comes to altered metabolism and psychiatric symtoms, and it has been suggested that thes

https://www.huntington-research.lu.se/article/congratulations-jennifer-her-first-publication-phd-student - 2026-09-13

Åsa Petersén has been interviewed by the website “Vetenskap & Hälsa” (Science & Health) about Huntington’s disease and the ongoing research to find a future treatment. Recent research has come up with some interesting findings, which are crucial for the development of efficient treatments.Link to the pod on the Vetenskap & Hälsa website – in Swedish only (opens in a new window)

https://www.huntington-research.lu.se/article/pod-huntingtons-disease-asa-petersen - 2026-09-13

For the first time ever, the four Swedish patients’ organizations for Alzheimer’s, Huntington, Parkinson’s and ALS are arranging a joint conference on neurodegenerative diseases. Åsa Petersén, Professor and Senior Consultant in Psychiatry, and Håkan Widner, Professor and Senior Consultant in Neurology, both active at the Huntington Disease Centre in Lund, will be taking part in a panel discussion

https://www.huntington-research.lu.se/article/mds-huntington-centre-lund-take-part-swedish-conference - 2026-09-13

After nearly four years' of PhD studies it is time for Sofia Bergh to defend her thesis in early May. Date and time: 6 May 2026 at 13.00Venue: The Belfrage Lecture Hall, BMC D15, Klinikgatan 32, LundAll welcome!

https://www.huntington-research.lu.se/article/sofia-bergh-phd-thesis-defence-6-may-2026 - 2026-09-13

On 6 May Sofia Bergh defended her thesis. The afternoon started with opponent Professor Gillian Bates, University College London, presenting the field of research and then Sofia talked about her published papers and work done during the PhD student years.Questions and discussion followed and then it was time for the examining committee deliberations. It was a fairly short meeting before the decisi

https://www.huntington-research.lu.se/article/congratulations-dr-bergh - 2026-09-13

From European Huntington Association:Join us for an open webinar with Novartis to get the latest updates on the INVEST-HD trial, including timeline updates and insights from a clinical perspective.Featuring presentations by Beth Borowsky, Senior Global Programme Clinical Head in Neuroscience at Novartis, and Åsa Petersén, MD PhD from Lund University, followed by a Q&A moderated by Astri Arnesen.📅

https://www.huntington-research.lu.se/article/dr-petersen-webinar-eha-and-novartis-invest-hd-trial - 2026-09-13

The HD2026 Milton Wexler Biennial Symposium took place in Boston in August 2026, organized by the Huntington Disease Foundation. Around 300 invited participants discussed science over four days. The talks are summarised at HD Buzz:Link to HD Buzz' webpage (opens in a new window)  

https://www.huntington-research.lu.se/article/petersen-gives-talk-huntington-disease-foundations-conference-boston-august-2026 - 2026-09-13

Den här artikeln är över 5 år gammal, och informationen kan därför vara inaktuell. Diabetesstiftelsen i Storbritannien, Diabetes UK, har inlett ett samarbete med livsmedelskedjan Tesco, sedan Tesco beslutat samla in och skänka 10 miljoner pund, motsvarande över 100 miljoner svenska kronor till forskning om typ 1 diabetes. Inom 20 år tror man sig ha ett vaccin inom räckhåll. Dr Alasdair Rankin, for

https://www.diabetesportalen.lu.se/artikel/vaccin-mot-typ-1-diabetes-inom-tjugo-ar - 2026-09-13

Den här artikeln är över 5 år gammal, och informationen kan därför vara inaktuell. På senare år har man upptäckt ett 70-tal genetiska riskvarianter för diabetes, men fortfarande är TCF7L2 - känd som ”diabetesgenen” - den gen som innebär störst risk för att insjukna i typ 2 diabetes. Med hjälp av en ny metod, ”exon skipping”, vill Ola Hansson vid Lunds universitets Diabetescentrum fördjupa kunskape

https://www.diabetesportalen.lu.se/artikel/ny-metod-reparerar-skadade-gener - 2026-09-13

Den här artikeln är över 5 år gammal, och informationen kan därför vara inaktuell. Med hjälp av ett enkelt blodprov kan man i dag se att vissa personer i framtiden riskerar att insjukna i typ 2 diabetes. Anders Rosengren, forskare vid Lunds universitets Diabetescentrum och läkare vid Skåne universitetssjukhus i Malmö, håller nu på att studera hur man kan hitta nya behandlingar för personer med en

https://www.diabetesportalen.lu.se/artikel/inflammationshammande-lakemedel-ska-forhindra-diabetes-typ-2 - 2026-09-13

Den här artikeln är över 5 år gammal, och informationen kan därför vara inaktuell. Att höga blodsocker kraftigt ökar risken för hjärt- kärlsjukdom är väl känt. Varför det är så är mer oklart. En viktig del av förklaringen kan vara NFAT, ett protein som aktiveras när blodsockret är förhöjt och som då startar en kedja av händelser som skadar blodkärlen och accelererar åderförkalkning. Nu vet forskar

https://www.diabetesportalen.lu.se/artikel/proteinblockad-stoppar-diabetiska-karlskador - 2026-09-13

Den här artikeln är över 5 år gammal, och informationen kan därför vara inaktuell. Patienter med diabetes typ 2 behandlas ofta med blodförtunnande läkemedel för att förebygga hjärt- och kärlsjukdomar. Men diabetespatienter som inte haft stroke, hjärtinfarkt eller andra hjärtsjukdomar blir inte hjälpta av blodförtunnande läkemedel. Det visar en studie av forskare vid Sahlgrenska akademin. yp 2 diab

https://www.diabetesportalen.lu.se/artikel/diabetespatienter-behover-inte-blodfortunnande-lakemedel - 2026-09-13